LUND, SWEDEN -- (MARKET WIRE) -- September 07, 2006 -- Active Biotech (ACTI.ST) publishes a new scientific paper - “Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer” - in the next issue of the scientific journal “Prostate” (pre-available as an e-publication at NCBI National Center for Biotechnology, http://www.ncbi.nlm.nih.gov/) in collaboration with Professor John T. Isaacs of Johns Hopkins University in Baltimore, USA.
